Gilead, Galapagos share 52-week update on filgotinib

Gilead, Galapagos share 52-week update on filgotinib

Source: 
Fierce Biotech
snippet: 

Gilead and Galapagos have said that 52-week phase 3 data for JAK1 inhibitor filgotinib in rheumatoid arthritis are consistent with earlier readouts. The update comes as Gilead prepares to make the case that filgotinib is safe and effective to the FDA.